Takeda Pharmaceutical Company Limited

(NYSE:TAK)

Latest On Takeda Pharmaceutical Company Limited (TAK):

Date/Time Type Description Signal Details
2023-05-12 02:55 ESTNewsTakeda Pharmaceutical Company Limited (TAK) Q4 2022 Earnings Call TranscriptN/A
2023-05-11 12:50 ESTNewsTakeda Pharmaceutical Non-GAAP EPS of ¥558.00, revenue of ¥4.03B; initiates FY23 guidanceN/A
2023-05-11 12:50 ESTNewsTakeda FY22 sales grow but FY23 outlook weighed down by generic impactN/A
2023-04-27 12:16 ESTNewsCorza Medical buys Takeda's TachoSil manufacturing operationsN/A
2023-04-27 12:16 ESTNewsTakeda's refiling for subcutaneous Entyvio gets FDA reviewN/A
2023-04-20 15:38 ESTNewsTakeda, Canadian Blood Services ink pact for immunodeficiency disease drugsN/A
2023-04-12 10:06 ESTNewsAdaptive Biotechnologies stock pops on Takeda pact for use of clonoSEQ testN/A
2023-04-11 20:54 ESTNewsCentogene stock surges ~15% on extending diagnostic pact with TakedaN/A
2023-04-04 23:10 ESTNewsArrowhead to get $40M milestone as Takeda starts fazirsiran dosing in liver disease trialN/A
2023-04-03 12:36 ESTNewsWhy Do We Keep Buying Takeda Pharmaceutical SharesN/A
2023-04-03 12:36 ESTNewsInnate stock surges ~15% after license deal with TakedaN/A
2023-03-30 19:25 ESTNewsTakeda's Entyvio meets primary endpoint in post-market studyN/A
2023-03-24 18:55 ESTNewsTakeda to invest ¥100B for new plasma-derived drugs facility in JapanN/A
2023-03-20 21:35 ESTNewsTakeda hits main goals in mid-stage trial for plaque psoriasis therapyN/A
2023-03-17 01:48 ESTNewsTakeda raised to Buy at BofA on growth prospects and debt repaymentN/A
2023-03-16 10:16 ESTNewsTakeda: Pipeline Expanding But Growth Worries PersistN/A
2023-02-20 15:44 ESTNewsTakeda Entyvio meets main goal in phase 3 trial to prevent intestinal acute graft-versus-host diseaseN/A
2023-02-14 15:49 ESTNewsSchrödinger gets $111.3M linked to Takeda's acquisition of Nimbus' psoriasis drugN/A
2023-02-03 01:39 ESTNewsTakeda Pharmaceutical Company Limited (TAK) Q3 2023 Earnings Call TranscriptN/A
2023-02-03 01:39 ESTNewsTakeda Pharmaceutical Company Limited 2023 Q3 - Results - Earnings Call PresentationN/A
2023-02-02 11:36 ESTNewsTakeda Pharmaceutical Non-GAAP EPS of ¥456.00, revenue of ¥3071.3B; reaffirms full-year guidanceN/A
2023-02-01 23:14 ESTNewsTakeda Pharmaceutical Q3 Earnings PreviewN/A
2023-01-23 09:12 ESTNewsTakeda to acquire rights to Hutchmed's cancer drug fruquintinib for $400M upfrontN/A
2023-01-19 12:28 ESTNewsTakeda Pharmaceutical Company (TAK) Presents At 41st Annual Healthcare Conference - SlideshowN/A
2023-01-11 16:28 ESTNewsTakeda's Exkivity gets approval in China for lung cancer subtypeN/A
2023-01-09 09:48 ESTNewsArrowhead stock dips ~15% amid phase 2 data for liver disease drug fazirsiranN/A
2023-01-05 16:13 ESTNewsTakeda posts positive Phase 3 data for clotting disorder candidateN/A
2022-12-22 06:13 ESTNewsAstellas Pharma, Eisai, Daiichi Sankyo and Takeda join hands to reduce environmental burden in the field of pharmaceutical packagingN/A
2022-12-15 18:57 ESTNewsTakeda's Takeout Of Nimbus And The 3 Amigos In The TYK2 Market - A Story With A Happy Ending?N/A
2022-12-13 15:07 ESTNewsTakeda to acquire Nimbus' potential psoriasis drug for $4B upfrontN/A
2022-12-13 15:06 ESTNewsTakeda Pharmaceutical Company Limited 2022 Q2 - Results - Earnings Call PresentationN/A
2022-12-13 15:06 ESTNewsTakeda: Late-Stage Pipeline Catalysts Approaching, But Vyvanse Patent Expiration LoomsN/A
2022-12-08 17:01 ESTNewsTakeda's dengue vaccine Qdenga gets approval in EUN/A
2022-12-07 03:53 ESTNewsTakeda: Momentum Building Around Core Offerings, Rate BuyN/A
2022-12-01 20:43 ESTNewsTakeda gets Canadian drug agency's backing for reimbursement of LivtencityN/A
2022-11-23 22:09 ESTNewsTakeda dengue vaccine gets FDA priority reviewN/A
2022-11-17 12:58 ESTNewsTakeda's Iclusig beats Novartis Glivec in phase 3 leukemia trialN/A
2022-11-11 20:16 ESTNewsTakeda Livtencity gets approval in EU for cytomegalovirus infection in transplant patientsN/A
2022-11-11 20:16 ESTNewsTakeda's blood clot disorder therapy gets EMA panel nod for expanded useN/A
2022-11-01 18:12 ESTNewsModerna's Omicron BA.4-5 targeting booster shot gets approval in JapanN/A
2022-10-27 17:27 ESTNewsTakeda Pharmaceutical Non-GAAP EPS of ¥288.00, revenue of ¥1974.8B; raises FY22 guidanceN/A
2022-10-27 17:26 ESTNewsTakeda Pharmaceutical Company Limited (TAK) Q2 2022 Earnings Call TranscriptN/A
2022-10-20 08:21 ESTNewsTakeda inks licensing deal for gluten disorder therapyN/A
2022-10-14 09:49 ESTNewsTakeda's dengue vaccine Qdenga gets EMA panel backing for approval in EUN/A
2022-10-05 14:05 ESTNewsTakeda seeks expanded FDA nod of its swelling attacks therapy to include kids aged 2-12N/A
2022-10-04 23:43 ESTNewsTakeda to discontinue production of hypoparathyroidism treatment in 2024N/A
2022-09-21 00:46 ESTNewsTakeda gets Canadian approval for its antiviral maribavir to treat cytomegalovirusN/A
2022-09-21 00:46 ESTNewsPuma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertibN/A
2022-09-19 14:36 ESTNewsTakeda signs 12-year virtual power purchase deal with EnelN/A
2022-09-16 18:36 ESTNewsTakeda wins EU nod for antiviral targeting cytomegalovirusN/A

About Takeda Pharmaceutical Company Limited (TAK):

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; and strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

TAK Quotes by TradingView

See Advanced Chart

General

  • Name Takeda Pharmaceutical Company Limited
  • Symbol TAK
  • Type Common Stock
  • Exchange NYSE
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryDrug Manufacturers-Specialty & Generic
  • Full Time Employees 47,495
  • Fiscal Year EndMarch
  • IPO Date2008-10-27
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Web URLhttp://www.takeda.com
View More

Valuation

  • Trailing PE 23.78
  • Forward PE 10.55
  • Price/Sales (Trailing 12 Mt.) 2.1
  • Price/Book (Most Recent Quarter) 1.45
  • Enterprise Value Revenue 0.03
  • Enterprise Value EBITDA 0.11
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate $0.85
  • Next Year EPS Estimate $0.97
  • Profit Margin 6%
  • Return on Assets 1%
  • Return on Equity 4%
  • Earnings Per Share $0.81
  • Revenue Per Share $0
  • Gross Profit 2.2 trillion
  • Quarterly Earnings Growth -2.6%
View More

Highlights

  • Market Capitalization 61.57 billion
  • PE Ratio 51.15
  • PEG Ratio 0.14
  • Analyst Target Price $22.79
  • Book Value Per Share $12.55
View More

Share Statistics

  • Shares Outstanding 3.15 billion
  • Shares Float 3.13 billion
  • % Held by Insiders <1%
  • % Held by Institutions 3.5%
  • Shares Short 6.57 million
  • Shares Short Prior Month 6.19 million
  • Short Ratio 1.52
View More

Technicals

  • Beta 1.11
  • 52 Week High $19.67
  • 52 Week Low $13.11
  • 50 Day Moving Average 17.7
  • 200 Day Moving Average 17.77
View More

Dividends

  • Forward Annual Dividend Rate $0.85
  • Forward Annual Dividend Yield 4.4%
  • Payout Ratio 39%
  • Dividend Date 2009-12-15
  • ExDividend Date 2020-09-29
  • Dividend Per Share $1.64
  • Dividend Yield 4.06%
View More

Takeda Pharmaceutical Company Limited (TAK) Dividend Calendar:

Takeda Pharmaceutical Company Limited pays an annual dividend of $0.85 per share, with a dividend yield of 4.06%.
TAK's last dividend payment was made to shareholders on December 15, 2009.
Takeda Pharmaceutical Company Limited pays out 39% of its earnings out as a dividend.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Takeda Pharmaceutical Company Limited (TAK) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-05$836.75 billion$0.28
2020-09-302020-11-02$N/A$1.10$103.00-98.93%
2020-06-302020-07-31$N/A$0.25$0.79-68.66%
2020-03-312020-05-13$771.7 billion$0.55
2019-12-312020-02-04$7.91 billion$3.00$75.00-96%
2019-09-302019-11-13$7.5 billion$0.16
2019-06-302019-07-31$7.84 billion-$0.06
2019-03-312019-05-14$6.44 billion-$0.16
2018-12-312019-02-01$4.56 billion$0.21
2018-09-302018-10-31$3.78 billion$0.28
2018-06-302018-07-31$4.06 billion$0.46
2018-03-312018-05-14$3.79 billion-$0.32
2017-12-312018-02-01$4.33 billion$0.38
2017-09-302017-11-01$0.16
2017-06-302017-07-28$0.83
2017-03-312017-05-10-$0.29
2016-12-312017-02-01$0.24
2016-09-302016-10-28$0.15
2016-06-302016-07-29$0.59
2016-03-312016-05-10-$0.19
2015-12-312016-02-03$0.31
2015-09-302015-10-30$0.15
2015-06-302015-07-30$0.13
2015-03-312015-05-15-$1.20
2014-12-312015-02-05$0.10
2014-09-302014-10-30$0.17
2014-06-302014-08-01$0.21
2014-03-312014-05-08-$0.13
2013-12-312014-02-05$0.29
2013-09-302013-10-31$0.23
2013-06-302013-07-31$0.19
2013-03-312013-05-09-$0.05
2012-12-312013-02-04$0.15
2012-09-302012-10-31$0.26
2012-06-302012-07-30$0.69
2012-03-312012-05-11-$0.29
2011-12-312012-02-01$0.20
2011-09-302011-11-04$0.49
2011-06-302011-07-29$0.59
2011-03-312011-05-11$0.25
2010-12-312011-02-03$0.55
2010-09-302010-10-29$0.60
2010-06-302010-07-30$0.45
2008-09-302008-11-04$0.39
2008-06-302008-07-31$0.01
2008-03-312008-05-09$0.14

Takeda Pharmaceutical Company Limited (TAK) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Takeda Pharmaceutical Company Limited (TAK) Chart:

Takeda Pharmaceutical Company Limited (TAK) News:

Below you will find a list of latest news for Takeda Pharmaceutical Company Limited (TAK) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Takeda Pharmaceutical Company Limited (TAK) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-05-152.50CALL0 0680.77TRUE00
2026-05-1550CALL0 0433.74TRUE00
2026-05-157.50CALL0 0273.7TRUE00
2026-05-15100CALL0 0184.82TRUE00
2026-05-1512.50CALL0 0126.81TRUE00
2026-05-15150CALL0 076.16TRUE00
2026-05-1517.50.1CALL1 10034.98FALSE0.10
2026-05-15200.1CALL0 11789.14FALSE00
2026-05-1522.50CALL0 0161.94FALSE00
2026-05-15250CALL0 0196.07FALSE00
2026-05-15300CALL0 0250.56FALSE00
2026-05-15350CALL0 0293.39FALSE00
2026-05-152.50.12PUT0 5494.62FALSE00
2026-05-1550PUT0 0678.57FALSE00
2026-05-157.50PUT0 0373.63FALSE00
2026-05-15100PUT0 0259.1FALSE00
2026-05-1512.50PUT0 0168.39FALSE00
2026-05-15150.07PUT5 42346.74FALSE-0.08-0.53
2026-05-1517.51.3PUT0 4627.74TRUE00
2026-05-15203.5PUT0 10TRUE00
2026-05-1522.50PUT0 00TRUE00
2026-05-15250PUT0 00TRUE00
2026-05-15300PUT0 0137.22TRUE00
2026-05-15350PUT0 0170.47TRUE00
2026-06-182.50CALL0 0297.37TRUE00
2026-06-1850CALL0 0189.17TRUE00
2026-06-187.50CALL0 0143.3TRUE00
2026-06-18100CALL0 096.75TRUE00
2026-06-1812.50CALL0 065.76TRUE00
2026-06-18151.75CALL0 1023.09TRUE00
2026-06-1817.50.5CALL23 154731.12FALSE0.050.11
2026-06-18200CALL0 059.92FALSE00
2026-06-1822.50CALL0 080.51FALSE00
2026-06-18250CALL0 097.37FALSE00
2026-06-18300CALL0 0124.31FALSE00
2026-06-18350CALL0 0145.48FALSE00
2026-06-182.50PUT0 0628FALSE00
2026-06-1850PUT0 0380.94FALSE00
2026-06-187.50PUT0 0184.6FALSE00
2026-06-18100PUT0 0127.91FALSE00
2026-06-1812.50.05PUT0 3282.99FALSE00
2026-06-18150.15PUT1 154029.18FALSE0.150
2026-06-1817.50PUT0 024.58TRUE00
2026-06-18200PUT0 00TRUE00
2026-06-1822.56.15PUT0 00TRUE00
2026-06-18250PUT0 00TRUE00
2026-06-18300PUT0 069.07TRUE00
2026-06-18350PUT0 00TRUE00
2026-07-172.50CALL0 0243.26TRUE00
2026-07-1750CALL0 0169.65TRUE00
2026-07-177.50CALL0 0124.35TRUE00
2026-07-17100CALL0 089.89TRUE00
2026-07-1712.50CALL0 360.47TRUE00
2026-07-17151.85CALL0 18334.72TRUE00
2026-07-1717.50.55CALL65 73831.98FALSE00
2026-07-17200.11CALL1 73332.1FALSE0.110
2026-07-1722.50CALL0 3852.58FALSE00
2026-07-17250.12CALL0 2552.52FALSE00
2026-07-17300CALL0 0103.43FALSE00
2026-07-17350CALL0 0120.42FALSE00
2026-07-172.50PUT0 1490.18FALSE00
2026-07-1750PUT0 0207.69FALSE00
2026-07-177.50PUT0 0143.87FALSE00
2026-07-17100PUT0 099.62FALSE00
2026-07-1712.50PUT0 30361.36FALSE00
2026-07-17150.3PUT0 22833.28FALSE00
2026-07-1717.51.5PUT0 27420.49TRUE00
2026-07-17203.36PUT0 10TRUE00
2026-07-1722.50PUT0 035.36TRUE00
2026-07-17250PUT0 00TRUE00
2026-07-17300PUT0 00TRUE00
2026-07-17350PUT0 00TRUE00
2026-10-162.50CALL0 0195.96TRUE00
2026-10-16511.68CALL0 1131.36TRUE00
2026-10-167.50CALL0 098.76TRUE00
2026-10-16100CALL0 070.67TRUE00
2026-10-1612.54.2CALL0 647.62TRUE00
2026-10-16153.1CALL0 7141TRUE00
2026-10-1617.50.9CALL0 2929.97FALSE00
2026-10-16200.25CALL0 30230.5FALSE00
2026-10-1622.50.25CALL0 13339.01FALSE00
2026-10-16250.21CALL0 455.41FALSE00
2026-10-16300CALL0 065.7FALSE00
2026-10-16350.25CALL0 181.28FALSE00
2026-10-162.50PUT0 0220.08FALSE00
2026-10-1650PUT0 0139.05FALSE00
2026-10-167.50PUT0 0103.32FALSE00
2026-10-16100PUT0 071.8FALSE00
2026-10-1612.50.22PUT0 233.46FALSE00
2026-10-16150.42PUT0 227.37FALSE00
2026-10-1617.51.17PUT0 326.98TRUE00
2026-10-16200PUT0 021.75TRUE00
2026-10-1622.50PUT0 00TRUE00
2026-10-16258.33PUT0 00TRUE00
2026-10-16300PUT0 00TRUE00
2026-10-16350PUT0 00TRUE00

Latest TAK Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST100$13.18
Jun 13, 2022 7:59 PM EST5$13.185
Jun 13, 2022 7:59 PM EST100$13.185
Jun 13, 2022 7:59 PM EST395$13.185
Jun 13, 2022 7:59 PM EST5$13.175

Takeda Pharmaceutical Company Limited (TAK) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395064/000139506420000122/0001395064-20-000122-index.htm
2019-08-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1395064/000000000019012497/0000000000-19-012497-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395064/000083423720006759/0000834237-20-006759-index.htm
2020-07-09CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1395064/000087666120000553/0000876661-20-000553-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395064/000094562120000061/0000945621-20-000061-index.htm
2019-11-06SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395064/000110465919060139/0001104659-19-060139-index.htm
2019-11-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395064/000117911019011437/0001179110-19-011437-index.htm
2019-05-20SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395064/000119312519151456/0001193125-19-151456-index.htm
2019-05-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000119312519160545/0001193125-19-160545-index.htm
2019-05-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000119312519161779/0001193125-19-161779-index.htm
2019-06-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000119312519172962/0001193125-19-172962-index.htm
2019-06-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000119312519172969/0001193125-19-172969-index.htm
2019-06-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000119312519174175/0001193125-19-174175-index.htm
2019-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000119312519175179/0001193125-19-175179-index.htm
2020-06-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000119312520177563/0001193125-20-177563-index.htm
2020-06-24F-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuershttps://www.sec.gov/Archives/edgar/data/1395064/000119312520177693/0001193125-20-177693-index.htm
2020-06-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000119312520178182/0001193125-20-178182-index.htm
2020-06-25424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395064/000119312520178198/0001193125-20-178198-index.htm
2020-06-25424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395064/000119312520178205/0001193125-20-178205-index.htm
2020-06-30FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1395064/000119312520183171/0001193125-20-183171-index.htm
2020-06-30FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1395064/000119312520183261/0001193125-20-183261-index.htm
2020-06-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000119312520183271/0001193125-20-183271-index.htm
2020-06-30424B2Prospectus [Rule 424(b)(2)]https://www.sec.gov/Archives/edgar/data/1395064/000119312520183299/0001193125-20-183299-index.htm
2020-06-30424B2Prospectus [Rule 424(b)(2)]https://www.sec.gov/Archives/edgar/data/1395064/000119312520183322/0001193125-20-183322-index.htm
2020-07-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000119312520190209/0001193125-20-190209-index.htm
2020-07-098-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1395064/000119312520190236/0001193125-20-190236-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395064/000120919119042489/0001209191-19-042489-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395064/000120919119054013/0001209191-19-054013-index.htm
2019-06-2720-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000005/0001395064-19-000005-index.htm
2019-06-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000006/0001395064-19-000006-index.htm
2019-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000008/0001395064-19-000008-index.htm
2019-07-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000011/0001395064-19-000011-index.htm
2019-07-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000013/0001395064-19-000013-index.htm
2019-07-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000015/0001395064-19-000015-index.htm
2019-07-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000017/0001395064-19-000017-index.htm
2019-08-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000019/0001395064-19-000019-index.htm
2019-08-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000022/0001395064-19-000022-index.htm
2019-08-09F-4Registration of securities, foreign private issuers, business combinationshttps://www.sec.gov/Archives/edgar/data/1395064/000139506419000024/0001395064-19-000024-index.htm
2019-09-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000027/0001395064-19-000027-index.htm
2019-09-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395064/000139506419000029/0001395064-19-000029-index.htm
2019-10-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000035/0001395064-19-000035-index.htm
2019-10-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000037/0001395064-19-000037-index.htm
2019-11-06SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1395064/000139506419000040/0001395064-19-000040-index.htm
2019-11-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000042/0001395064-19-000042-index.htm
2019-11-12F-4/ARegistration of securities, foreign private issuers, business combinationshttps://www.sec.gov/Archives/edgar/data/1395064/000139506419000050/0001395064-19-000050-index.htm
2019-11-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1395064/000139506419000052/0001395064-19-000052-index.htm
2019-11-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000058/0001395064-19-000058-index.htm
2019-11-14424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000060/0001395064-19-000060-index.htm
2019-11-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000062/0001395064-19-000062-index.htm
2019-11-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000064/0001395064-19-000064-index.htm
2019-11-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000067/0001395064-19-000067-index.htm
2019-11-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000072/0001395064-19-000072-index.htm
2019-11-22SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395064/000139506419000080/0001395064-19-000080-index.htm
2019-11-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395064/000139506419000081/0001395064-19-000081-index.htm
2019-11-22SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395064/000139506419000082/0001395064-19-000082-index.htm
2019-11-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395064/000139506419000083/0001395064-19-000083-index.htm
2019-11-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000085/0001395064-19-000085-index.htm
2019-12-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506419000088/0001395064-19-000088-index.htm
2020-01-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000003/0001395064-20-000003-index.htm
2020-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000007/0001395064-20-000007-index.htm
2020-01-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000010/0001395064-20-000010-index.htm
2020-01-24SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395064/000139506420000020/0001395064-20-000020-index.htm
2020-01-24SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395064/000139506420000021/0001395064-20-000021-index.htm
2020-01-27SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1395064/000139506420000024/0001395064-20-000024-index.htm
2020-02-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000029/0001395064-20-000029-index.htm
2020-02-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000030/0001395064-20-000030-index.htm
2020-02-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000033/0001395064-20-000033-index.htm
2020-02-26POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1395064/000139506420000037/0001395064-20-000037-index.htm
2020-03-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000040/0001395064-20-000040-index.htm
2020-04-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000043/0001395064-20-000043-index.htm
2020-04-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000045/0001395064-20-000045-index.htm
2020-05-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000052/0001395064-20-000052-index.htm
2020-05-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000054/0001395064-20-000054-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000056/0001395064-20-000056-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000058/0001395064-20-000058-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000060/0001395064-20-000060-index.htm
2020-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000068/0001395064-20-000068-index.htm
2020-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000070/0001395064-20-000070-index.htm
2020-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000073/0001395064-20-000073-index.htm
2020-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000075/0001395064-20-000075-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000078/0001395064-20-000078-index.htm
2020-06-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395064/000139506420000081/0001395064-20-000081-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395064/000139506420000082/0001395064-20-000082-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395064/000139506420000084/0001395064-20-000084-index.htm
2020-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000087/0001395064-20-000087-index.htm
2020-06-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000090/0001395064-20-000090-index.htm
2020-06-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000105/0001395064-20-000105-index.htm
2020-06-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000106/0001395064-20-000106-index.htm
2020-06-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000107/0001395064-20-000107-index.htm
2020-06-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000108/0001395064-20-000108-index.htm
2020-06-2420-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000110/0001395064-20-000110-index.htm
2020-06-25S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1395064/000139506420000113/0001395064-20-000113-index.htm
2020-06-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000115/0001395064-20-000115-index.htm
2020-06-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000118/0001395064-20-000118-index.htm
2020-06-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000120/0001395064-20-000120-index.htm
2020-06-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395064/000139506420000122/0001395064-20-000122-index.htm
2020-07-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000124/0001395064-20-000124-index.htm
2020-07-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000132/0001395064-20-000132-index.htm
2020-07-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000133/0001395064-20-000133-index.htm
2020-08-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000138/0001395064-20-000138-index.htm
2020-08-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000141/0001395064-20-000141-index.htm
2020-08-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000144/0001395064-20-000144-index.htm
2020-08-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000147/0001395064-20-000147-index.htm
2020-09-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000150/0001395064-20-000150-index.htm
2020-10-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000153/0001395064-20-000153-index.htm
2020-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000158/0001395064-20-000158-index.htm
2020-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000160/0001395064-20-000160-index.htm
2020-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1395064/000139506420000162/0001395064-20-000162-index.htm
2019-11-14EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1395064/999999999519002568/9999999995-19-002568-index.htm
2020-03-02EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1395064/999999999520000449/9999999995-20-000449-index.htm

Takeda Pharmaceutical Company Limited (TAK) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Takeda Pharmaceutical Company Limited (TAK). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: < 1%
Institutional Ownership: 350%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-06-30Shire Human Genetic Therapies, Inc.10% Share HolderSell6,824,992.0020.68141,140,834.560.00https://www.sec.gov/Archives/edgar/data/1395064/000139506420000122/0001395064-20-000122-index.htm
2019-10-08PHARMACEUTICAL CO LTD TAKEDA10% Share HolderBuy2,000,000.002.505,000,000.005,750,000.00https://www.sec.gov/Archives/edgar/data/1395064/000139506419000083/0001395064-19-000083-index.htm
2020-06-03Shire Human Genetic Therapies, Inc.10% Share HolderSell40,086.0019.75791,698.506,824,992.00https://www.sec.gov/Archives/edgar/data/1395064/000139506420000084/0001395064-20-000084-index.htm
2020-06-02Shire Human Genetic Therapies, Inc.10% Share HolderSell5,006.0020.02100,220.126,865,078.00https://www.sec.gov/Archives/edgar/data/1395064/000139506420000082/0001395064-20-000082-index.htm
2020-06-02Shire Human Genetic Therapies, Inc.10% Share HolderSell100,389.0019.751,982,682.756,870,084.00https://www.sec.gov/Archives/edgar/data/1395064/000139506420000082/0001395064-20-000082-index.htm
2020-06-01Shire Human Genetic Therapies, Inc.10% Share HolderSell1,400.0020.5328,742.006,970,473.00https://www.sec.gov/Archives/edgar/data/1395064/000139506420000082/0001395064-20-000082-index.htm
2020-06-01Shire Human Genetic Therapies, Inc.10% Share HolderSell107,072.0019.852,125,379.206,971,873.00https://www.sec.gov/Archives/edgar/data/1395064/000139506420000082/0001395064-20-000082-index.htm